The Supervisory Board of Sartorius AG has extended the appointment of Dr. René Fáber as a member of the Executive Board by five years, through December 31, 2031. The decision, made at today's meeting, underscores the board's confidence in Faber's strategic leadership of the Bioprocess Solutions Division, a key segment of the life science group.
René Fáber, 50, holds a Ph.D. in polymer chemistry from the Technical University of Munich. He joined Sartorius in 2002 as a scientist and advanced through various management roles before being appointed to the Executive Board in January 2019. His extended tenure ensures continuity in the company's strategic direction, particularly in bioprocess solutions, which are critical for the production of biotech drugs, vaccines, and cell and gene therapies.
Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The company operates through two divisions: Lab Products & Services, which focuses on laboratory instruments and consumables, and Bioprocess Solutions, which provides single-use solutions for safer, faster, and more sustainable production. With around 60 production and sales locations worldwide, Sartorius generated sales revenue of approximately 3.5 billion euros in 2025 and employs more than 14,000 people globally.
The extension of Faber's contract comes as Sartorius continues to strengthen its portfolio through acquisitions and organic growth. The company regularly supplements its offerings with complementary technologies, and its strong global presence positions it well to serve the evolving needs of the biopharmaceutical industry. For more details on Faber's career, a CV is available here.
Investors and stakeholders can mark key financial dates: April 23, 2026, for first quarter results; July 23, 2026, for half-year results; and October 22, 2026, for nine-month results. The full financial calendar is accessible on the company's website.
This leadership stability is important for Sartorius as it navigates the dynamic biopharmaceutical landscape, where demand for innovative manufacturing solutions continues to rise. Faber's extended term ensures that the Bioprocess Solutions Division will maintain its strategic focus under experienced leadership, supporting the company's mission to enable safer and more efficient drug production worldwide.
